Literature DB >> 14754444

Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer.

Malcolm Frier1.   

Abstract

The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14754444     DOI： 10.2174/1389557043487510

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  4 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  The development of copper radiopharmaceuticals for imaging and therapy.

Authors:  Monica Shokeen; Thaddeus J Wadas
Journal:  Med Chem       Date:  2011-09       Impact factor: 2.745

3.  Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back.

Authors:  Byeong-Cheol Ahn
Journal:  Theranostics       Date:  2012-04-11       Impact factor: 11.556

Review 4.  188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy.

Authors:  Alessandra Boschi; Petra Martini; Licia Uccelli
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.